Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor RelationsGlobeNewsWire • 08/16/21
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/09/21
Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021GlobeNewsWire • 07/26/21
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®GlobeNewsWire • 07/19/21
Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development OfficerGlobeNewsWire • 07/06/21
Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of DirectorsGlobeNewsWire • 06/29/21
Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®GlobeNewsWire • 06/28/21
Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in JapanGlobeNewsWire • 06/28/21
Catalyst (CPRX) Up 18.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/09/21
Catalyst Pharmaceuticals, Inc.'s and KYE Pharmaceuticals' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®GlobeNewsWire • 06/03/21
Catalyst Pharmaceuticals: Undervalued Cash Flow Generator With High Probability Of OutperformanceSeeking Alpha • 05/31/21
Catalyst Pharmaceuticals' (CPRX) CEO Patrick McEnany on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 05/10/21
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q1 Earnings Expected to DeclineZacks Investment Research • 05/03/21